CoChat

Polyomavirus Enhancer-binding Protein 2/Core Binding Factor/Acute Myeloid Leukemia Factors Contribute to the Cell Type-specific Activity of the CD11a Integrin Gene Promoter

Open access
Puig-Kröger, Amaya, López-Rodrı́guez, Cristina, Relloso, Miguel, Sánchez-Elsner, Tilman, Nueda, Arsenio, Muñoz, Eduardo, Bernabéu, Carmelo, Corbı́, Angel L. · 2000 · Journal of Biological Chemistry

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

The CD11a/CD18 leukocyte integrin (LFA-1; also known as alphaL/beta2) mediates leukocyte transendothelial migration during immune and inflammatory responses and participates in lymphoma metastasis. CD11a/CD18 leukocyte-restricted expression is controlled by the CD11a gene promoter, which confers tissue-specific expression to reporter genes in vitro and in vivo. DNase I protection analysis of the CD11a proximal gene promoter revealed DNA-protein interactions centered at position -110 (CD11a-110). Disruption of CD11a-110 reduced CD11a promoter activity in a cell type-specific manner, as it reduced its activity by 70% in Jurkat lymphoid cells, whereas the effect was considerably lower in K562 and HepG2 cells. Electrophoretic mobility shift assays showed evidence of cell type-specific differences in CD11a-110 binding and indicated its specific recognition by members of the polyomavirus enhancer-binding protein 2/core binding factor (CBF)/acute myeloid leukemia (AML) family of transcription factors. AML1B/CBFbeta transactivated the CD11a promoter, with AML1B/CBFbeta-mediated transactivation being completely dependent on the integrity of the CD11a-110 element. Therefore, CBF/AML factors play a role in the cell type-restricted transcription of the CD11a integrin gene through recognition of CD11a-110. The involvement of CBF/AML factors in CD11a expression raises the possibility that CD11a/CD18 expression might be deregulated in acute myeloid and B-lineage acute lymphoblastic leukemias, thus contributing to their altered adhesion and metastatic potential.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m004323200

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1 DNase I protection analysis of the proximal region (-170/ 1 43) of the CD11a promoter. Probe was incubated with nuclear extracts from Jurkat ( J ) or HeLa ( H ) (50 m g in the left panel and 30 or 50 m g in the right panel ). Lanes marked - contained 50 m g of bovine serum albumin. After digestion with DNase I, samples were analyzed on denaturing polyacrylamide gels in parallel with G 1 A sequence ladders generated with the same probe to precisely map each band. Panels show the footprints obtained in the sense ( left panel ) and antisense ( middle and right panels ) strands.
FIG. 1 DNase I protection analysis of the proximal region (-170/ 1 43) of the CD11a promoter. Probe was incubated with nuclear extracts from Jurkat ( J ) or HeLa ( H ) (50 m g in the left panel and 30 or 50 m g in the right panel ). Lanes marked - contained 50 m g of bovine serum albumin. After digestion with DNase I, samples were analyzed on denaturing polyacrylamide gels in parallel with G 1 A sequence ladders generated with the same probe to precisely map each band. Panels show the footprints obtained in the sense ( left panel ) and antisense ( middle and right panels ) strands.CC-BY · From the PDF
FIG. 2 Nuclear factors interacting with the MS7 probe and identification of nucleotides involved in recognition of CD11a110. All panels show EMSA performed on the MS7 oligonucleotide using nuclear extracts from Jurkat leukemic T cells, B lymphoblastoid JY cells, erythroleukemic K562 cells, and phorbol myristate acetatedifferentiated K562 cells, as indicated. Major specific retarded complexes are indicated by an asterisk (AML-110). Unlabeled competitor oligonucleotides (MS4, MS6, MS7, MS9, MS7MUT, AP2CONS, and NFkBCONS) were added at 100-fold molar excess.
FIG. 2 Nuclear factors interacting with the MS7 probe and identification of nucleotides involved in recognition of CD11a110. All panels show EMSA performed on the MS7 oligonucleotide using nuclear extracts from Jurkat leukemic T cells, B lymphoblastoid JY cells, erythroleukemic K562 cells, and phorbol myristate acetatedifferentiated K562 cells, as indicated. Major specific retarded complexes are indicated by an asterisk (AML-110). Unlabeled competitor oligonucleotides (MS4, MS6, MS7, MS9, MS7MUT, AP2CONS, and NFkBCONS) were added at 100-fold molar excess.CC-BY · From the PDF
FIG. 3 The CD11a-110 element affects the CD11a promoter activity in a cell type-specific manner. Jurkat, K562, and HepG2 cells were transfected with pCD11A170-Luc, the corresponding mutant at the CD11a-110 element (pCD11A170(-110mut)-Luc), or the promoterless vector pXP2, and luciferase activity was determined. Each experiment was performed at least three times using distinct DNA preparations, and a representative experiment is shown. Promoter activity is expressed relative to the activity produced by the wild-type pCD11A170-Luc reporter plasmid in each transfected cell line, after normalization for transfection efficiency. Wild-type and mutant CD11a110 sites are depicted as filled and open circles, respectively.
FIG. 3 The CD11a-110 element affects the CD11a promoter activity in a cell type-specific manner. Jurkat, K562, and HepG2 cells were transfected with pCD11A170-Luc, the corresponding mutant at the CD11a-110 element (pCD11A170(-110mut)-Luc), or the promoterless vector pXP2, and luciferase activity was determined. Each experiment was performed at least three times using distinct DNA preparations, and a representative experiment is shown. Promoter activity is expressed relative to the activity produced by the wild-type pCD11A170-Luc reporter plasmid in each transfected cell line, after normalization for transfection efficiency. Wild-type and mutant CD11a110 sites are depicted as filled and open circles, respectively.CC-BY · From the PDF
FIG. 4 Members of the AML/PEBP2/CBF family of transcription factors recognize the CD11a-110 element. EMSA was performed on the MS7 and AML1CONS oligonucleotide probes using nuclear extracts from Jurkat leukemic T cells or B lymphoblastoid JY cells in the absence (-) or presence of unlabeled competitor oligonucleotides (MS7, MS7MUT, and AML1CONS) or polyclonal antisera against AML proteins (R-3034 and anti-AML1). Unlabeled competitor oligonucleotides were added at a 100-fold molar excess.
FIG. 4 Members of the AML/PEBP2/CBF family of transcription factors recognize the CD11a-110 element. EMSA was performed on the MS7 and AML1CONS oligonucleotide probes using nuclear extracts from Jurkat leukemic T cells or B lymphoblastoid JY cells in the absence (-) or presence of unlabeled competitor oligonucleotides (MS7, MS7MUT, and AML1CONS) or polyclonal antisera against AML proteins (R-3034 and anti-AML1). Unlabeled competitor oligonucleotides were added at a 100-fold molar excess.CC-BY · From the PDF
FIG. 5 Recognition of CD11a-110 by AML1, AML3, and CBF b -enriched cell extracts. EMSA performed on the MS7 oligonucleotide probe using cellular extracts from COS-7 cells transfected with either CMV-0, CMV-AML1B, CMV-AML3, or CMV-CBF b . Binding reactions were performed in the absence (-) or presence of unlabeled competitor oligonucleotides (MS7, MS7MUT, or AML1CONS) at a 100-fold molar excess.
FIG. 5 Recognition of CD11a-110 by AML1, AML3, and CBF b -enriched cell extracts. EMSA performed on the MS7 oligonucleotide probe using cellular extracts from COS-7 cells transfected with either CMV-0, CMV-AML1B, CMV-AML3, or CMV-CBF b . Binding reactions were performed in the absence (-) or presence of unlabeled competitor oligonucleotides (MS7, MS7MUT, or AML1CONS) at a 100-fold molar excess.CC-BY · From the PDF
FIG. 6 AML/CBF factors transactivate the CD11a integrin gene promoter. K562 cells were transfected with 1 m g of pCD11A170Luc together with the indicated amounts (in m g) of CMV-0, CMVAML1B, or CMV-CBF b expression plasmids. The luciferase units produced by each transfection experiment are indicated. In all cases, total DNA was kept constant. Each experiment was repeated at least four times, and a representative experiment is shown.
FIG. 6 AML/CBF factors transactivate the CD11a integrin gene promoter. K562 cells were transfected with 1 m g of pCD11A170Luc together with the indicated amounts (in m g) of CMV-0, CMVAML1B, or CMV-CBF b expression plasmids. The luciferase units produced by each transfection experiment are indicated. In all cases, total DNA was kept constant. Each experiment was repeated at least four times, and a representative experiment is shown.CC-BY · From the PDF
FIG. 7 AML/CBF transactivation of the CD11a promoter is dependent on the integrity of the CD11a-110 element. K562 cells were transfected with 1 m g of pCD11A170-Luc or pCD11A-(110mut)Luc together with the indicated amounts (in m g) of CMV-0, CMVAML1B, or CMV-CBF b expression plasmids. The luciferase units produced by each transfection experiment are indicated. In all cases, total DNA was kept constant. Each experiment was repeated at least four times with two distinct DNA preparations, and a representative experiment is shown.
FIG. 7 AML/CBF transactivation of the CD11a promoter is dependent on the integrity of the CD11a-110 element. K562 cells were transfected with 1 m g of pCD11A170-Luc or pCD11A-(110mut)Luc together with the indicated amounts (in m g) of CMV-0, CMVAML1B, or CMV-CBF b expression plasmids. The luciferase units produced by each transfection experiment are indicated. In all cases, total DNA was kept constant. Each experiment was repeated at least four times with two distinct DNA preparations, and a representative experiment is shown.CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Research works printed but not linked: 5

  1. 18. Bae, S.-C., and Ito, Y. (1999) Histol. Histopathol. 14, 1213-1221
  2. 19. Speck, N. A., Stacy, T., Wang, Q., North, T., Gu, T.-L., Miller, J., Binder, M., and Marı ´n-Padilla, M. (1999) Cancer Res. 59, Suppl., 1789s-1793s
  3. 27. Bottinger, E. P., Shelley, C. S., Farokhzad, O. C., and Arnaout, M. A. (1994) Mol. Cell. Biol. 14, 2604-2615
  4. 36. Suzow, J., and Friedman, A. D. (1993) Mol. Cell. Biol. 13, 2141-2151 - Cameron, S., Taylor, D. S., TePas, E. C., Speck, N. A., and Mathey-Privot, B.
  5. 38. Nuchprayoon, I., Meyers, S., Scott, L. M., Suzow, J., Hiebert, S., and Friedman, A. D. (1994) Mol. Cell. Biol. 14, 5558-5568

Cited by

See all 31

Metadata

Authors
Puig-Kröger, A., López-Rodrı́guez, C., Relloso, M., Sánchez-Elsner, T., Nueda, A., Muñoz, E., Bernabéu, C., & Corbı́, A. L.
Affiliations
Consejo Superior de Investigaciones Científicas (ES)
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2000-09
Volume
275
Issue
37
Pages
28507-28512
ISSN
0021-9258 (ISSN-L)
OpenAlex
W2027972283
Cited by
27
References
41
Citations by year
2025: 1 · 2022: 1 · 2015: 1 · 2014: 1 · 2012: 6
FWCI
1.08
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
  • Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
CD11a/CD18, LFA-1, beta2 integrins, promoter, transcriptional regulation, cell type-specific gene expression, core binding factor, transcription factor binding, leukocyte transendothelial migration, lymphoma metastasis, acute myeloid leukemia, B-cell acute lymphoblastic leukemia, leukocyte adhesion
MeSH terms
Cell Line, DNA-Binding Proteins, Humans, Promoter Regions, Genetic, Proto-Oncogene Proteins, Transcription Factors, Transcriptional Activation, Lymphocyte Function-Associated Antigen-1, CCAAT-Enhancer-Binding Proteins, Transcription Factor AP-2, Core Binding Factor Alpha 2 Subunit

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Polyomavirus Enhancer-binding Protein 2/Core Binding Factor/Acute Myeloid Leukemia Factors Contribute to the Cell Type-specific Activity of the CD11a Integrin Gene Promoter. https://app.cochat.ai/papers/10.1074/jbc.m004323200
The paper
Puig-Kröger, A., López-Rodrı́guez, C., Relloso, M., Sánchez-Elsner, T., Nueda, A., Muñoz, E., Bernabéu, C., & Corbı́, A. L. (2000). Polyomavirus Enhancer-binding Protein 2/Core Binding Factor/Acute Myeloid Leukemia Factors Contribute to the Cell Type-specific Activity of the CD11a Integrin Gene Promoter. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.m004323200

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.